NASDAQ: MACKMerrimack Pharmaceuticals Inc Stock
$14.71-0.02 (-0.14%)
Updated Apr 24, 2024
MACK Price
$14.71
Fair Value Price
$0.42
Market Cap
$213.53M
52 Week Low
$11.53
52 Week High
$15.89
P/E
-183.88x
P/B
11.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$2M
Beta
0.39
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MACK Overview
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MACK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MACK ($14.71) is overvalued by 3,412.08% relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MACK ($14.71) is not significantly undervalued (3,412.08%) relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MACK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MACK due diligence checks available for Premium users.
Be the first to know about important MACK news, forecast changes, insider trades & much more!
MACK News
Valuation
MACK fair value
Fair Value of MACK stock based on Discounted Cash Flow (DCF)
Price
$14.71
Fair Value
$0.42
Overvalued by
3,412.08%
MACK ($14.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MACK ($14.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MACK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MACK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-183.88x
Industry
15.69x
Market
41.27x
MACK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.39x
Industry
5.86x
MACK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MACK's financial health
Profit margin
Revenue
$0.0
Net Income
-$240.0k
Profit Margin
0%
MACK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.2M
Liabilities
$441.0k
Debt to equity
0.02
MACK's short-term assets ($19.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MACK's short-term assets ($19.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MACK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MACK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$295.0k
Investing
$68.0k
Financing
$133.0k
MACK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MACK vs Biotech Stocks
Merrimack Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.